Osteoporosis in postmenopausal women, prevention of osteoporosis in postmenopausal women and Paget's disease of bones
Osteoporosis in postmenopausal women: 10mg OD. Prevention of osteoporosis in post- menopausal women: 5mg OD. Paget's disease of bone: 40mg OD x 6/12.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
An aminobisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. It binds to the hydroxyapatite in bones.
Renal insufficiency; hypocalcemia and other disturbances of mineral metabolism need to be corrected before initiating therapy with this drug; tablets are taken with plain water the first thing in the morning (at least 30 minutes before the first food, beverage, or medication of the day).
Hypocalcemia; abnormalities of the esophagus which delay emptying such as stricture or achalasia; for those who cannot stand or sit upright for at least 30 minutes; hypersensitivity to any component of the product.
Side effects are generally rare and mild; GI disturbances; headache; taste perversion; musculo-skeletal pain; hypersensitivity reactions.